Literature DB >> 10205204

Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones.

M J Veysey1, L A Thomas, A I Mallet, P J Jenkins, G M Besser, J A Wass, G M Murphy, R H Dowling.   

Abstract

BACKGROUND: Treatment of acromegaly with octreotide increases the proportion of deoxycholic acid in, and the cholesterol saturation of, bile and induces the formation of gallstones. Prolongation of intestinal transit has been proposed as the mechanism for the increase in the proportion of deoxycholic acid in bile. AIMS: To study the effects of octreotide on intestinal transit in acromegalic patients during octreotide treatment, and to examine the relation between intestinal transit and bile acid composition in fasting serum.
METHODS: Mouth to caecum and large bowel transit times, and the proportion of deoxycholic acid in fasting serum were measured in non-acromegalic controls, acromegalic patients untreated with octreotide, acromegalics on long term octreotide, and patients with simple constipation. Intestinal transit and the proportion of deoxycholic acid were compared in acromegalic patients before and during octreotide.
RESULTS: Acromegalics untreated with octreotide had longer mouth to caecum and large bowel transit times than controls. Intestinal transit was further prolonged by chronic octreotide treatment. There were significant linear relations between large bowel transit time and the proportion of deoxycholic acid in the total, conjugated, and unconjugated fractions of fasting serum.
CONCLUSIONS: These data support the hypothesis that, by prolonging large bowel transit, octreotide increases the proportion of deoxycholic acid in fasting serum (and, by implication, in bile) and thereby the risk of gallstone formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205204      PMCID: PMC1727511          DOI: 10.1136/gut.44.5.675

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Increasing butyrate concentration in the distal colon by accelerating intestinal transit.

Authors:  S J Lewis; K W Heaton
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

2.  Degradation of bile salts by human intestinal bacteria.

Authors:  M J Hill; B S Drasar
Journal:  Gut       Date:  1968-02       Impact factor: 23.059

3.  Absorption of bile acids by the colon.

Authors:  J S Morris; K W Heaton; A E Read
Journal:  Gut       Date:  1970-12       Impact factor: 23.059

4.  Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans.

Authors:  L El Oufir; B Flourié; S Bruley des Varannes; J L Barry; D Cloarec; F Bornet; J P Galmiche
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

5.  Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.

Authors:  S H Hussaini; S P Pereira; M J Veysey; C Kennedy; P Jenkins; G M Murphy; J A Wass; R H Dowling
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

6.  7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones.

Authors:  F Berr; G A Kullak-Ublick; G Paumgartner; W Münzing; P B Hylemon
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

Review 7.  Role of intestinal transit in the pathogenesis of gallbladder stones.

Authors:  R H Dowling; M J Veysey; S P Pereira; S H Hussaini; L A Thomas; J A Wass; G M Murphy
Journal:  Can J Gastroenterol       Date:  1997 Jan-Feb       Impact factor: 3.522

8.  The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones.

Authors:  S H Hussaini; G M Murphy; C Kennedy; G M Besser; J A Wass; R H Dowling
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

Review 9.  Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.

Authors:  J S Redfern; W J Fortuner
Journal:  Am J Gastroenterol       Date:  1995-07       Impact factor: 10.864

10.  Absorption of bile acids from the large bowel in man.

Authors:  P Samuel; G M Saypoi; E Meilman; E H Mosbach; M Chafizadeh
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

View more
  17 in total

1.  High magnification chromoscopic colonoscopy as a screening tool in acromegaly.

Authors:  D P Hurlstone; S S Cross; A J Lobo; D S Sanders
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  Screening guidelines for colorectal cancer and polyps in patients with acromegaly.

Authors:  P J Jenkins; P D Fairclough
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 3.  Bile salt hydrolase activity in probiotics.

Authors:  Máire Begley; Colin Hill; Cormac G M Gahan
Journal:  Appl Environ Microbiol       Date:  2006-03       Impact factor: 4.792

Review 4.  Physical Activity and the Biliary Tract in Health and Disease.

Authors:  Roy J Shephard
Journal:  Sports Med       Date:  2015-09       Impact factor: 11.136

5.  Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones.

Authors:  A F Hofmann
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly.

Authors:  L A Thomas; M J Veysey; G M Murphy; D Russell-Jones; G L French; J A H Wass; R H Dowling
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

7.  Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.

Authors:  M T Sheehan; T B Nippoldt
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

8.  Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

Authors:  R Attanasio; A Mainolfi; F Grimaldi; R Cozzi; M Montini; C Carzaniga; S Grottoli; L Cortesi; M Albizzi; R M Testa; L Fatti; D De Giorgio; C Scaroni; F Cavagnini; P Loli; G Pagani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 9.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 10.  The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines.

Authors:  K Lois; J Bukowczan; P Perros; S Jones; M Gunn; R A James
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.